Newswire (Published: Tuesday, January 9, 2018, Received: Friday, January 5, 2018, 11:22:53 AM CST)

Word Count: 469

Researchers at University Hospital Bonn Release New Data on Prostate Cancer (Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy)

By a News Reporter-Staff News Editor at Cancer Weekly -- A new study on Oncology - Prostate Cancer is now available. According to news reporting out of Bonn, Germany, by NewsRx editors, research stated, "Prostate-specific membrane antigen (PSMA) is a promising target for the diagnosis of and therapy for metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to measure overall-survival (OS) in mCRPC patients who received either abiraterone or enzalutamide prior to PSMA therapy."

Our news journalists obtained a quote from the research from University Hospital Bonn, "The second aim of this study was to analyse the predictors of OS according to different pre-therapeutic parameters and also the responses to the first cycle of radioligand therapy (RLT) base on PSA level. Patients with mCRPC and a history of therapy with either abiraterone or enzalutamide or both, were included in this study. Different laboratory tests and pre-therapeutic parameters have been included into the analysis. One-hundred patients received a total of 347 cycles of Lu-PSMA (median: three cycles). 69 patients showed a decline in PSA two months after the first cycle, and 38 of those patients showed a PSA decline of= >50%. The median OS was 60 weeks. In the multivariate analysis, the level of albumin, AST and haemoglobin, existence of liver metastases and a decline of >14% in PSA level had a significant impact on overall-survival. The median OS is significantly longer in patients without hepatic involvement, with high levels of albumin and Hb and low levels of AST."

According to the news editors, the research concluded: "A decline in PSA levels of more than 14% was the most important response parameter with regard to overall survival."

For more information on this research see: Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy. Oncotarget, 2017;8(61):103108-103116 (see also Oncology - Prostate Cancer).

Our news journalists report that additional information may be obtained by contacting H. Ahmadzadehfar, Dept. of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. Additional authors for this research include S. Schlolaut, R. Fimmers, A. Yordanova, S. Hirzebruch, C. Schlenkhoff, F.C. Gaertner, Z.H. Awang, S. Hauser and M. Essler.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.18632/oncotarget.21600. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Bonn, Europe, Germany, Therapy, Oncology, Prostate Cancer, Health and Medicine, Prostatic Neoplasms.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

Industries

Healthcare
      Healthcare Facilities
            Hospitals

Places

Western Europe
Germany
Europe

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer